Brugada syndrome is a rare inherited arrhythmia syndrome leading to an increased risk of sudden cardiac death, despite a structurally normal heart. Diagnosis is based on a specific electrocardiogram pattern, observed either spontaneously or during a sodium channel blocker test. Among affected patients, risk stratification remains a challenge, despite recent insights from large population cohorts. As implantable cardiac defibrillators – the main therapy in Brugada syndrome – are associated with a high rate of complications in this population, the main challenge is risk stratification of patients with Brugada syndrome. Aside from the two main predictors of arrhythmia (symptoms and spontaneous electrocardiogram pattern), many risk factors have been recently suggested for stratifying risk of sudden cardiac death in Brugada syndrome. We have reviewed these data and discuss current guidelines in light of recent progress in this complex field.

Brugada syndrome: Diagnosis and risk stratification

Sciarra L
2010

Abstract

Brugada syndrome is a rare inherited arrhythmia syndrome leading to an increased risk of sudden cardiac death, despite a structurally normal heart. Diagnosis is based on a specific electrocardiogram pattern, observed either spontaneously or during a sodium channel blocker test. Among affected patients, risk stratification remains a challenge, despite recent insights from large population cohorts. As implantable cardiac defibrillators – the main therapy in Brugada syndrome – are associated with a high rate of complications in this population, the main challenge is risk stratification of patients with Brugada syndrome. Aside from the two main predictors of arrhythmia (symptoms and spontaneous electrocardiogram pattern), many risk factors have been recently suggested for stratifying risk of sudden cardiac death in Brugada syndrome. We have reviewed these data and discuss current guidelines in light of recent progress in this complex field.
Le syndrome de Brugada est une arythmie cardiaque héréditaire rare, responsable de mort subite. En l’absence de cardiopathie structurelle, le diagnostic repose sur l’ECG au repos ou lors d’un test de provocation pharmacologique. Comme le seul traitement ayant démontré sont efficacité est l’implantation d’un défibrillateur, mais qu’il s’accompagne d’un risque élevé de complication dans cette population, l’évaluation du risque rythmique est essentielle à la prise en charge de ces patients. Un aspect ECG spontané de syndrome de Brugada et la présence de symptômes restent les éléments les plus importants dans la stratification du risque mais de nombreux autres paramètres ont été récemment proposés pour stratifier le risque de mort subite. Nous discuterons l’analyse de l’ensemble de ces données au regard des dernières recommandations de prise en charge.
File in questo prodotto:
File Dimensione Formato  
2010 GiornItalCardiol Delise.pdf

accesso aperto

Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 527.31 kB
Formato Adobe PDF
527.31 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11697/177557
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact